Pfenex Inc. (PFNX) News
Filter PFNX News Items
PFNX News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Latest PFNX News From Around the Web
Below are the latest news stories about Pfenex Inc that investors may wish to consider to help them evaluate PFNX as an investment opportunity.
Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing a tender offer to purchase all outstanding shares of common stock of Pfenex, Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent payment of $2.00 in cash, if a certain |
PFENEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pfenex Inc. - PFNXNEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pfenex Inc. (NYSE: PFNX) to Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). Under the terms of the proposed transaction, shareholders of Pfenex will receive $12.00 in cash, and a one-time contingent value right of $2.00 in the event a predefined regulatory milestone is achieved by December 31, 2021, for |
Pfenex leads healthcare gainers; Mesoblast and Genesis Healthcare among losersGainers: Pfenex (PFNX) +67%. Eyenovia (EYEN) +44%. ProPhase Labs (PRPH) +38%. Trevi Therapeutics (TRVI) +20%. Pieris Pharmaceuticals (PIRS) +18%.Losers: Fulcrum Therapeutics (FULC) -44%. Mesoblast (MESO) -37%. Fennec Pharmaceuticals (FENC) -35%. Genesis Healthcare (GEN) -28%. PDS Biotechnology (PDSB) -24%.... |
Ligand Pharmaceuticals to acquire fellow San Diego biotech Pfenex for up to $516MLigand Pharmaceuticals is set to acquire Pfenex in the fourth quarter of 2020. The two San Diego biotechs rely on developing early-stage tools and licensing them out to other companies. |
SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.NEW YORK, Aug. 11, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pfenex, Inc. ("PFNX" or the "Company") (NYSE American: PFNX) in connection with the proposed acquisition of the Company by… |
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In SeptemberScaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (reacted to second-quarter results) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Fulgent Genetics Inc (NASDAQ: FLGT ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Omeros Corporation (NASDAQ: OMER ) ( announced positive results for the study of its lead asset in COVID-19) Pacira Biosciences Inc (NASDAQ: PCRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Seres Therapeutics Inc (NASDAQ: MCRB ) ( reacted to positive late-stage clinical r... |
Pfenex Reports Second Quarter 2020 Results and Provides Business UpdateCommercialization and launch of first royalty bearing products position company for next phase of growthMultiple U.S. health plans add Teriparatide… |
Earnings Preview: Pfenex (PFNX) Q2 Earnings Expected to DeclinePfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Pfenex to Announce Second Quarter Financial Results on August 6SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second… |
Hedge Funds Are Selling Pfenex Inc (PFNX)The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […] |